AUSTRALIAN-LISTED medical life science company Medlab Clinical Limited has been granted a 20-year patent covering the Australian market for its probiotic product, NRGBiotic.
The company announcement said that applications for patents were also underway in the United States, Europe and two Asian countries.
According to Medlab ceo Sean Hall, achieving a patent for NRGBiotic independently validates an important pillar of Medlab's science.
"To be granted a patent on our NRGBiotic product, Medlab needed to show uniqueness, usefulness and effectiveness," Hall said.
The product targets co-therapy in managing chronic diseases such as depression.
Along with probiotics and gut health, Medlab is also focused on Nanocelle delivery techology which is already being applied to a statin, and to forms of cannabis in trials.
NanaBis (tetrahydrocannabinol/ cannabidiol - THC/CBD) is under cannabis trial for advanced oncology patients with intractable pain while NanaBidial (CBD only) cannabis is in trials for patients with nausea, vomiting and seizures.
Medlab says it has five core research programs examining the role of bacteria in health: obesity, chronic kidney disease, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Sep 17
